Intrauterine Misoprostol versus intravenous Oxytocin infusion during cesarean delivery to reduce intraoperative and postoperative blood loss: a randomised clinical trial
Keywords:Cesarean section, Misoprostol, Oxytocin, Postpartum hemorrhage
Background: The objective of the present study was to compare the efficacy of intrauterine misoprostol with intravenous oxytocin infusion in reducing blood loss during and after cesarean section (CS).
Methods: An open, randomized, clinical trial, registered (ClinicalTrials.gov ID: NCT03148574) conducted between July 1, 2017 and April 1, 2018. The study included 240 pregnant females that were recruited at term (37-40 weeks) gestation scheduled for either elective or emergency CS. Eligible participants were randomly allocated into two equal groups: Group A: patients who receive intravenous infusion of 10 I.U diluted to 500ml of normal saline for 30 minute after delivery. Group B: patients received 400μg misoprostol intrauterine just after cord clamping and delivery of the placenta. Primary outcome measure was assessment of amount of intraoperative and postoperative blood loss.
Results: The intraoperative and 2h postoperative blood loss in the misoprostol group was higher than oxytocin group (p<0.001). Hemoglobin level decreased significantly among both groups, manifested by the highly significant p value in comparison of pre and postoperative Hb level in the two groups (p<0.001). However, the blood loss in the misoprostol group was higher than oxytocin group (p=0.004). There was a statistical significant differences between both groups as regards the need for additional uterotonic drug (66% in misoprostol group vs 5% in oxytocin group, P<0.001). Shivering and pyrexia were more in common in the misoprostol group while vomiting, headache and giddiness were significantly higher among oxytocin group.
Conclusions: Administration of misoprostol 400mcg through intrauterine route appears to be less effective than intravenous oxytocin infusion in reducing blood loss during and after CS.
Abbas AM, Amin MT, Ali SS, Salem NZ. Maternal mortality: a tertiary care hospital experience in Upper Egypt. Int J Reprod Contracept Obstet Gynecol. 2017;5(5):1466-71.
Getahun D, Strickland D, Lawrence JM, Fassett MJ, Koebnick C, Jacobsen SJ. Racial and ethnic disparities in the trends in primary cesarean delivery based on indications. Am J Obstet Gynecol. 2009;201:e1-7.
Brennan DJ, Robson MS, Murphy M, O’Herlihy C. Comparative analysis of international cesarean delivery rates using 10-group classification identifies significant variation in spontaneous labor. Am J Obstet Gynecol. 2009;201:e1-8.
Abdelaleem AA, Abbas AM, Thabet AL, Badran E, El-Nashar IH. The effect of initiating intravenous oxytocin infusion before uterine incision on the blood loss during elective cesarean section: a randomized clinical trial. J Maternal-Fetal Neonatal Med. 2018:1-6.
Acharya G, Al-Sammarai MT, Patel N, Al-Habib A, Kiserud T. A randomized, controlled trial comparing effect of oral misoprostol and intravenous syntocinon on intra-operative blood loss during cesarean section. Acta Obstet Gynecol Scand. 2001;80:245-50.
Munn MB, Owen J, Vincent R, Wakefield M, Chestnut DH, Hauth JC. Comparison of two oxytocin regimens to prevent uterine atony at cesarean delivery: a randomized controlled trial. Obstet Gynecol. 2001;98:386-90.
Hamm J, Russell Z, Botha T, Carlan SJ, Richichi K. Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study. Am J Obstet Gynecol. 2005;192:1404-6.
Vimala N, Mittal S, Kumar S. Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. Int J Gynaecol Obstet. 2006;92:106-10.
Othman ER, Fayez MF, El Aal DE, Mohamed HS, Abbas AM, Ali MK. Sublingual misoprostol versus intravenous oxytocin in reducing bleeding during and after cesarean delivery: A randomized clinical trial. Taiwanese J Obstet Gynecol. 2016;55(6):791-5.
Shady NW, Sallam HF, Elsayed AH, Abdelkader AM, Ali SS, Alanwar A, et al. The effect of prophylactic oral tranexamic acid plus buccal misoprostol on blood loss after vaginal delivery: a randomized controlled trial. J Maternal-Fetal Neonatal Med. 2017:1-7.
Metwaly AB, Abbas AM, Al-Sakkaf M. The use of single dose of oral misoprostol (600µg) at home in management of first trimester miscarriages in El-Mukala, Yemen. Int J Reprod Contracept Obstet Gynecol. 2017;5(5):1360-3.
Mitwaly AB, Abbas AM, Abdellah MS. Intra uterine extra-amniotic versus vaginal misoprostol for termination of second trimester miscarriage: A randomized controlled trial. Int J Reprod BioMed. 2016;14(10):643.
Mitwaly AB, Abbas AM. Intrauterine extra-amniotic misoprostol solution is effective for termination of second trimester missed abortion: a clinical pilot descriptive study. Thai J Obstet Gynaecol. 2017:6-10.
Maher MA, Sayyed TM, Elkhouly NI. Different routes and forms of uterotonics for treatment of retained placenta: a randomized clinical trial. J Maternal-Fetal Neonatal Med. 2017;30(18):2179-84.
Abbas AM. Different routes and forms of uterotonics for treatment of retained placenta: methodological issues. J Maternal-Fetal Neonatal Med. 2019;32(6):1048.
Abdellah MS, Abbas AM, Hegazy AM, El-Nashar IM. Vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective cesarean section: a randomized double-blind clinical trial. Contracept. 2017;95(6):538-43.
Khalaf M, Amin AF, Sayed Z, El-Nashar IM, Abbas AM. A randomized double-blind controlled trial of two different doses of self-administered vaginal misoprostol for successful copper intrauterine device insertion. Middle East Fertil Soc J. 2017;22(4):264-8.
Samy A, Abbas AM, Mahmoud M, Taher A, Awad MH, Hussein M, et al. Evaluating different pain lowering medications during intrauterine device insertion: a systematic review and network meta-analysis. Fertil Steril. 2019.
Duthie SJ, Ven D, Yung GL, Guang DZ, Chan SY. Discrepancy between laboratory determination and visual estimation of blood loss during normal delivery. Eur J Obstet Gynecol Reprod Biol. 1991;38(2):119-24.
Vimala, N, Mittal S, Kumar S. Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. Int J Gynecol Obstet. 2006;92(2):106-10.
Owonikoko KM, Arowojolu AO, Okunlola MA. Effect of sublingual misoprostol versus intravenous oxytocin on reducing blood loss at cesarean section in Nigeria: a randomized controlled trial. J Obstet Gynaecol Res. 2011;37(7):715-21.
Kavle JA, Khalfan SS, Stoltzfus RJ, Witter F, Tielsch JM, Caulfield LE. Measurement of blood loss at childbirth and postpartum. Int J Gynecol Obstet. 2006;95(1):24-8.
Quiroga DR, Cantú MR, Tello GHE, Puente VM, Montemayor GR, Martínez MA. Intrauterine misoprostol for the prevention of bleeding cesarean. Ginecol Obstet Mex. 2009;77(10):469-74.
Xueqin ZH. Clinical observation of intrauterine placement Misoprostol in prevention of intraoperative and postoperative bleeding in cesarean section. China Medical Herald. 2010;25:039.